Baidu
map

美国Theranos公司将用几滴血颠覆体检方式

2015-07-06 许青 译 健康报

7月4日,就是美国举国欢庆的日子了。不过Theranos公司的创始人伊丽莎白·霍尔姆斯不用等到这一天就可以开始庆祝了。7月2日,Theranos专有的验血系统得到了美国食品与药品监督管理局(FDA)的认可,这么傲人的业绩霍尔姆斯不用等到国庆日就可以开香槟庆祝了! Theranos的名片是其独特的验血方式,只需从手指上扎出几滴血便可完成。昨天,这个装血样的小瓶和Theranos的验血程序都获得了美

7月4日,就是美国举国欢庆的日子了。不过Theranos公司的创始人伊丽莎白·霍尔姆斯不用等到这一天就可以开始庆祝了。7月2日,Theranos专有的验血系统得到了美国食品与药品监督管理局(FDA)的认可,这么傲人的业绩霍尔姆斯不用等到国庆日就可以开香槟庆祝了!


Theranos的名片是其独特的验血方式,只需从手指上扎出几滴血便可完成。昨天,这个装血样的小瓶和Theranos的验血程序都获得了美国食品和药品管理局的许可。Theranos简单的验血方式对于过度洁癖者和需要频繁验血的人格外有吸引力,此外其价格低廉透明也令人惊讶--它所提供的153种血液检查都在10美元以下,彻底将价格排除在了考虑因素之外。

验血只是一种检查方式,霍尔姆斯的终极目标是通过简化验血程序,让人们主动了解自己的健康状况,从而及时发现一些疾病,彻底改变早期疾病检查方式。


实际上血液检查并不需要FDA的认证,但是Theranos从2013年开始就在努力获得审批。而这一审批来的也相当及时,因为得到审批的第二天其与与亚利桑那州共同起草的法案就生效了。该法案允许病人在没有医生单据的情况下进行血液检查。这标志着霍尔姆斯又向其终极目标迈进了一步。霍尔姆斯说:“该法案的通过表明我们可以建立一种全新的医生-患者关系。如果人们都参与进来,他们完全可以主动监督自己的健康状况,不用等到生病后才去验血检查。”

除了可以提高患者主动关心自身健康外,由于其将验血结果的解释责任摊给了患者自己,该法案还在一定程度上保护了医生的权益。

霍尔姆斯说:“该法案有意保护医生免于吃官司,但是我们也尽最大努力确保医生和病人之间能建立一个有效的咨询环境。”为此Theranos还成立了一个网上信息平台--MDConnect,让亚利桑那州验血者与该州的基础护理医生可以在网上交流。霍尔姆斯说:“这就像是做孕检,你不需要得到医生的许可才能去做,你可以先去做了检查然后再去找医生咨询检查结果。我们所做的这一切都是希望给病人提供了解自己的健康状况的有效途径。”


Theranos走到今天也遇到过一些批评。由于至今没有公开公司进行血液检查的设备和方式,Theranos被指进行“隐秘研究”。今年2月,斯坦福大学医学院的教授John Ioannidis就在美国医学协会的一份期刊上就批评Theranos进行“隐秘研究”,并要求该公司公开自己的设备和测验方法。

Theranos在血液检查上的主要竞争对手Quest和LabCorp并未对此作出回应。霍尔姆斯也只简单地说:“有很多人都在批评我们,但是那都不是真的。”

各界评论
DeciBio的一名生物科技分析师Eric Lakin说:“这个法案的通过是Theranos迈出的一大步,而FDA的认证也使Theranos的核心竞争力得以有效发挥。但是Theranos依然有很长的路要走。而我最担心的是血液检测结果的解读上。”

Eric Meyer之前是一名急诊医生,现在是亚利桑那州众议院少数派的领袖和众议院卫生委员会的成员,他最关心的是Theranos可以帮助亚利桑那州减少医疗花费。Meyer说:“作为一名医生,我很喜欢让患者更主动地管理自己的健康这个点子,但是作为立法者,可以降低医疗费用这一点更让我兴奋。如果你不需要经常验血,那么Theranos可能起不到什么作用,但是如果需要,它会完全颠覆传统方式。”

住在凤凰城的Cole就是一个例子。这个8岁的孩子患有亚斯伯格综合症,但是很害怕抽血,每次抽血对他来说都是噩梦。但是在Theranos的实验室,看到技术人员不慌不忙,整个过程Cole竟然也接受了抽血,后来竟然还自己要求回去抽血,因为他觉得“自己是个男子汉了。”

也正是诸如此类的案例不断推动者Theranos的发展,霍尔姆斯说:“我们从不关心其他公司在做什么,我们只关心如何做好早期疾病检测。”她还透露Theranos或将转战美国其他州。霍尔姆斯说:“我们先爬,再走,再学会跑,一步一步慢慢打下坚实的基础,于我而言这就是最重要的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=105970, encodeId=979a1059e055, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:39:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049873, encodeId=057520498e39e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sun Apr 03 02:07:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738775, encodeId=feab1e387759c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Jul 20 13:07:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34801, encodeId=e28134801ee, content=只要通过临床试验验证,有没有公开技术无关紧要, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Thu Aug 06 11:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33261, encodeId=d3343326119, content=真的:-), beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f0f106091, createdName=acount, createdTime=Wed Jul 22 00:14:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31629, encodeId=f6b7316293d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:27:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305080, encodeId=ab71130508034, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jul 08 05:07:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=105970, encodeId=979a1059e055, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:39:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049873, encodeId=057520498e39e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sun Apr 03 02:07:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738775, encodeId=feab1e387759c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Jul 20 13:07:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34801, encodeId=e28134801ee, content=只要通过临床试验验证,有没有公开技术无关紧要, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Thu Aug 06 11:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33261, encodeId=d3343326119, content=真的:-), beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f0f106091, createdName=acount, createdTime=Wed Jul 22 00:14:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31629, encodeId=f6b7316293d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:27:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305080, encodeId=ab71130508034, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jul 08 05:07:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2016-04-03 海豹
  3. [GetPortalCommentsPageByObjectIdResponse(id=105970, encodeId=979a1059e055, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:39:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049873, encodeId=057520498e39e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sun Apr 03 02:07:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738775, encodeId=feab1e387759c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Jul 20 13:07:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34801, encodeId=e28134801ee, content=只要通过临床试验验证,有没有公开技术无关紧要, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Thu Aug 06 11:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33261, encodeId=d3343326119, content=真的:-), beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f0f106091, createdName=acount, createdTime=Wed Jul 22 00:14:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31629, encodeId=f6b7316293d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:27:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305080, encodeId=ab71130508034, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jul 08 05:07:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=105970, encodeId=979a1059e055, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:39:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049873, encodeId=057520498e39e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sun Apr 03 02:07:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738775, encodeId=feab1e387759c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Jul 20 13:07:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34801, encodeId=e28134801ee, content=只要通过临床试验验证,有没有公开技术无关紧要, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Thu Aug 06 11:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33261, encodeId=d3343326119, content=真的:-), beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f0f106091, createdName=acount, createdTime=Wed Jul 22 00:14:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31629, encodeId=f6b7316293d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:27:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305080, encodeId=ab71130508034, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jul 08 05:07:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-08-06 shneye

    只要通过临床试验验证,有没有公开技术无关紧要

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=105970, encodeId=979a1059e055, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:39:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049873, encodeId=057520498e39e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sun Apr 03 02:07:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738775, encodeId=feab1e387759c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Jul 20 13:07:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34801, encodeId=e28134801ee, content=只要通过临床试验验证,有没有公开技术无关紧要, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Thu Aug 06 11:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33261, encodeId=d3343326119, content=真的:-), beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f0f106091, createdName=acount, createdTime=Wed Jul 22 00:14:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31629, encodeId=f6b7316293d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:27:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305080, encodeId=ab71130508034, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jul 08 05:07:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-22 acount

    真的:-)

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=105970, encodeId=979a1059e055, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:39:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049873, encodeId=057520498e39e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sun Apr 03 02:07:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738775, encodeId=feab1e387759c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Jul 20 13:07:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34801, encodeId=e28134801ee, content=只要通过临床试验验证,有没有公开技术无关紧要, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Thu Aug 06 11:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33261, encodeId=d3343326119, content=真的:-), beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f0f106091, createdName=acount, createdTime=Wed Jul 22 00:14:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31629, encodeId=f6b7316293d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:27:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305080, encodeId=ab71130508034, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jul 08 05:07:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-08 huaxipanxing

    看看

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=105970, encodeId=979a1059e055, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:39:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049873, encodeId=057520498e39e, content=<a href='/topic/show?id=852b1e3838b' target=_blank style='color:#2F92EE;'>#Theranos#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17383, encryptionId=852b1e3838b, topicName=Theranos)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3289320, createdName=海豹, createdTime=Sun Apr 03 02:07:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738775, encodeId=feab1e387759c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Jul 20 13:07:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34801, encodeId=e28134801ee, content=只要通过临床试验验证,有没有公开技术无关紧要, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b159816, createdName=shneye, createdTime=Thu Aug 06 11:55:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33261, encodeId=d3343326119, content=真的:-), beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f0f106091, createdName=acount, createdTime=Wed Jul 22 00:14:00 CST 2015, time=2015-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31629, encodeId=f6b7316293d, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:27:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305080, encodeId=ab71130508034, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jul 08 05:07:00 CST 2015, time=2015-07-08, status=1, ipAttribution=)]
    2015-07-08 marongnuan

相关资讯

JBC:验血可检测癌症基因

Texas大学MD Anderson癌症中心的科学家们发现,癌细胞释放到血液中的胞外体(Exosome),包含了癌细胞的整个遗传学蓝图。这一基因组数据可以用于检测癌症相关的突变,帮助医生尽早诊断癌症,以便对患者进行有效治疗。文章发表在本期的Journal of Biological Chemistry杂志上。 领导这项研究的Raghu Kalluri教授指出,未来可以

Am J Psychiatry:验血或可预知自杀风险

美国研究人员30日说,他们开发出一种新方法,通过验血便可预知一个人的自杀风险。不过,这种验血方法仍需更大规模的研究进一步证实。 美国约翰斯·霍普金斯大学研究人员在《美国精神病学杂志》上报告说,这种验血方法主要依赖于检测一种叫做SKA2 的基因是否发生特定变异,一旦发现这种变异,那么便可预测病患有较大自杀风险。 “自杀是一种可预防的重大公共健康问题,但我们一直缺乏一致的方法来进行预测,

SCI TRANSL MED:验血有望查出癌症

人们通常在出现症状或者进行诸如乳房X射线检查等筛查时,才发现自己患上了癌症。一般而言,即使癌症筛查也只能在肿瘤已经生长出来或是扩散后才能检查出来,这时癌症已经很难治愈。 不过,在肿瘤初期时,人们能从简单、精度高的血液检查中发现什么?现在,通过排序肿瘤释放在患者血流内的异常DNA,研究人员朝用常规血液检查检测癌症迈出了重要一步。 虽然研究显示,该技术目前仅对晚期癌症足够敏感,但是

Mol Psychiatr:验血能预知自杀风险?

假如精神病学家仅仅通过提取的血液样本判断某人是否会自杀,那么情形将会怎样? 据Science Now报道,现在一项最新研究发现,考虑自杀的人血液中的某种特定蛋白质数量会上升,这一结果被发表在8月20日的《自然》旗下子刊《分子精神病学》(Molecular Psychiatry)上。但这一试验所选择的研究对象非常有限,考虑到从长远角度看,这种类型的“生物指标”往往被证明是不可靠的,将其用于临床应用

Mol.Psychiatry:美研究发现验血可能帮助诊断抑郁症

由美国麻省总医院(MGH)的研究人员等组成的团队报告称,某项分析九个生物标志物水平的检测可准确区分抑郁症患者与对照参与者,而没有显着假阳性结果。相关论文发表在《分子精神病学》(Molecular Psychiatry)杂志上。 “传统上,抑郁症与其他精神障碍的诊断基于患者报告的症状;但该过程的准确性变异非常大,往往取决于进行评估的临床医师的临床经验与资源,”本报告的第一与通讯作者——麻省总医院精

NEJM:验血可预测前列腺癌治疗疗效

最近,约翰霍普金斯大学Sidney Kimmel综合癌症研究中心研究人员带领的一项研究表明,如果前列腺癌患者的肿瘤含有一种称为AR-V7的蛋白质——可在血液中检测到,那么他们在经过两种广泛使用的转移性前列腺癌药物治疗后,很可能没有疗效。 研究人员称,如果这些结果能够通过大规模研究而得以验证,那么,假如一位前列腺癌患者具有可检测到的ARV7血液水平,他就应该避免使用这两种药物,而是采取其他药物治疗。

Baidu
map
Baidu
map
Baidu
map